News

Ideas That Generate Results

According to a new research report by RNCOS entitled, “Global Gene Therapy Market Outlook 2018”, “Glybera” formally became the first gene therapy to be approved in a regulated market in Europe. Glybera is a gene therapy developed by the Amsterdam based company UniQure. The therapy is designed to restore the LPL enzyme activity required to enable the processing, or clearance, of fat-carrying chylomicron particles formed in the intestine after a fat-containing meal.
 
Glybera would initially be sold in Germany 'with the first commercial treatments expected in the first half of 2015. Earlier in 2013, UniQure announced collaboration agreement with Chiesi pharmaceutical SpA for the commercialization of Glybera. Under the agreement Chiesi has exclusive rights to commercialize Glybera in the EU and selected additional territories. Further UniQure had received EUR 17 Million (US$ 21.8 Million) in collaboration financing, and EUR 14 Million (US$ 18 Million) in equity financing from Chiesi.
 
The report is spread in over 120 pages and provides an in-depth research and rational analysis of the global gene therapy market. A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the gene therapy market such as phases, geographies, vector types, etc. A brief overview of the key geographies in the gene therapy segment and the regulatory scenario governing the industry has also been included in the study to present a balanced outlook.
 
The report covers how major trends and drivers, including nanotechnology, advanced therapies to treat chronic diseases etc will propel the industry’s growth. With a view to understand the competitive landscape, the profiles of key market players are included in the report to present a complete picture of the global gene therapy market.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM715.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm